Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-fluorouracil with or without docetaxel

Autor: Ahmad Awada, Jan B. Vermorken, J. R. Germà-Lluch, Ioannis S. Pateras, Amanda Psyrri, M. Degardin, Christos Kroupis, Catherine Fortpied, Margaritis Avgeris, Heinz Roland Kienzer, Jessica Menis, George Koutsodontis, L. Herman, Nikolaos Goutas, Lisa Licitra, Johannes A. Langendijk, Livia Giurgea, Éva Remenár, C.M.L. van Herpen
Přispěvatelé: Damage and Repair in Cancer Development and Cancer Treatment (DARE), Guided Treatment in Optimal Selected Cancer Patients (GUTS)
Jazyk: angličtina
Rok vydání: 2017
Předmět:
0301 basic medicine
Oncology
Male
OROPHARYNGEAL CANCER
NETHERLANDS
Docetaxel
Polymerase Chain Reaction
0302 clinical medicine
Antineoplastic Combined Chemotherapy Protocols
Medicine
EPIDEMIOLOGY
Viral
Head and neck cancer
human papillomavirus
Papillomaviridae
In Situ Hybridization
E6
Oropharyngeal cancer
TPF induction chemotherapy
virus diseases
Hematology
ASSOCIATION
PREVALENCE
Fluorouracil
Head and Neck Neoplasms
030220 oncology & carcinogenesis
Carcinoma
Squamous Cell
SURVIVAL
Female
Taxoids
EORTC 24971/TAX323 phase III clinical trial
HPV16
Human papillomavirus
Cisplatin
DNA
Viral
Humans
Polymorphism
Restriction Fragment Length
Retrospective Studies
Squamous Cell Carcinoma of Head and Neck
Survival Analysis
medicine.drug
Rare cancers Radboud Institute for Health Sciences [Radboudumc 9]
Subset Analysis
medicine.medical_specialty
03 medical and health sciences
Internal medicine
Polymorphism
business.industry
Carcinoma
HUMAN-PAPILLOMAVIRUS
Cancer
P16
DNA
medicine.disease
Head and neck squamous-cell carcinoma
Cancérologie
Regimen
030104 developmental biology
Restriction Fragment Length
Squamous Cell
head and neck cancer
Human medicine
business
Hématologie
Zdroj: Annals of Oncology, 28, 2213-2218
Annals of Oncology, 28(9), 2213-2218. Oxford University Press
Annals of Oncology, 28, 9, pp. 2213-2218
Annals of oncology
Annals of oncology, 28 (9
ISSN: 1569-8041
0923-7534
DOI: 10.1093/annonc/mdx320
Popis: Background: EORTC 24971 was a phase III trial demonstrating superiority of induction regimen TPF (docetaxel, cisplatin, 5-fluorouracil) over PF (cisplatin/5-fluorouracil), in terms of progression-free (PFS) and overall survival (OS) in locoregionally advanced unresectable head and neck squamous cell carcinomas. We conducted a retrospective analysis of prospectively collected data aiming to evaluate whether only HPV(-) patients (pts) benefit from adding docetaxel to PF, in which case deintensifying induction treatment in HPV(+) pts could be considered. Patients and methods: Pretherapy tumor biopsies (blocks or slides) were assessed for high-risk HPV by p16 immunohistochemistry, PCR and quantitative PCR. HPV-DNA+and/or p16+tumors were subjected to in situ hybridization (ISH) and HPV E6 oncogene expression qRT-PCR analysis. Primary and secondary objectives were to evaluate the value of HPV/p16 status as predictive factor of treatment benefit in terms of PFS and OS. The predictive effect was analyzed based on the model used in the primary analysis of the study with the addition of a treatment by marker interaction term and tested at two-sided 5% significance level. Results: Of 358, 119 pts had available tumor samples and 58 of them had oropharyngeal cancer. Median follow-up was 8.7 years. Sixteen of 119 (14%) evaluable samples were p16+and 20 of 79 (25%) evaluable tumors were HPV-DNA+. 13 of 40 pts (33%) assessed with HPV-DNA ISH and 12 of 28 pts (43%) assessed for HPV E6 mRNA were positive. The preplanned analysis showed no statistical evidence of predictive value of HPV/p16 status for PFS (P=0.287) or OS (P=0.118). Conclusions: The incidence of HPV positivity was low in the subset of EORTC 24971 pts analyzed. In this analysis only powered to detect a large treatment by marker interaction, there was no statistical evidence that treatment effect found overall was different in magnitude in HPV(+) or HPV(-) pts. These results do not justify selection of TPF versus PF according to HPV status.
SCOPUS: ar.j
info:eu-repo/semantics/published
Databáze: OpenAIRE
Externí odkaz: